Patent · US Active

AAV treatment of Huntington's disease

US10457940B2 · kind B2 · utility

2Cited by

20References

22Claims

0Family size

Assignee

University of Massachusetts · US

Inventors

Christian Mueller · Wiesbaden, DE
Neil Aronin · Newton, US
Edith Pfister · Boxborough, US

Key dates

Filing date	Sep 15, 2017
Grant date	Oct 29, 2019
Priority date	—
Expiry date	Sep 15, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2750/14171
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Aspects of the disclosure relate to compositions and methods useful for treating Huntington's disease. In some embodiments, the disclosure provides interfering nucleic acids (e.g., artificial miRNAs) targeting the huntingtin gene (HTT) and methods of treating Huntington's disease using the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.